Participating investigators randomly assigned ( with an interactive voice response system ) patients @:@ to receive an intravenous infusion of nivolumab @ mg/kg every @ weeks or ICC ( dacarbazine @ mg/m ( @ ) every @ weeks or paclitaxel @ mg/m ( @ ) combined with carboplatin area under the curve @ every @ weeks ) until progression or unacceptable toxic effects .